Mirtazapin Teva (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapin Teva, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral dosage form for oral use. It is indicated for the treatment of major depressive disorder in adult patients. The medication works by modulating neurotransmitter activity, thereby improving mood and alleviating depressive symptoms.

GNH USA supplies Mirtazapin Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and research institutions worldwide.

Mirtazapine is used primarily in the management of depressive disorders.

- Major depressive disorder (single episode): reduces depressive symptoms and improves functional status. - Major depressive disorder (recurrent): helps maintain remission and prevent relapse. - Depressive symptoms with anxiety comorbidity: may improve both mood and anxiety levels.

Mirtazapine may cause a range of adverse reactions, which are generally categorized by frequency.

Common Side Effects: - Sedation or drowsiness. - Increased appetite and weight gain. - Dry mouth. - Constipation. - Dizziness. - Orthostatic hypotension.

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia. - Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Suicidal thoughts or worsening depression. - Severe hypotension or syncope. - Seizures.

Before initiating therapy, clinicians should consider several safety measures.

- Monitor for worsening depression or emergence of suicidal thoughts: assess patients regularly, especially during early treatment. - Use with caution in patients with hepatic impairment: dose adjustment may be required. - Avoid abrupt discontinuation: taper under medical supervision to reduce withdrawal risk. - Exercise caution in elderly patients: increased sedation may raise fall risk. - Assess for hypersensitivity reactions: discontinue if rash or angioedema occurs. - Store at room temperature: keep in original packaging, protect from moisture and light.

Mirtazapine can interact with several drug classes, necessitating careful review of a patient’s medication list.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome. - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): may precipitate serotonin syndrome. - Central nervous system depressants (e.g., benzodiazepines, alcohol): additive sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirtazapine plasma levels. - CYP3A4 inducers (e.g., carbamazepine, rifampicin): may reduce efficacy. - Anticoagulants (e.g., warfarin): monitor INR for potential changes.